Please login to order a test.
VistaSeq℠ Hereditary Cancer Panel
The following genes are assessed: APC, ATM, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, FAM175A, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PRKAR1A, PTEN, RAD51C, RAD51D, SMAD4, STK11, TP53.
VistaSeq℠ provides an assessment of inherited genetic mutations within a panel of 27 genes known to be associated with hereditary cancer syndromes.
Each gene sequence is interpreted independently of all other gene sequences; however, variants in different genes may sometimes interact to cause or modify a typically monogenic disease phenotype. It cannot be excluded that pathogenic variants were missed due to limitations inherent in the sequence analysis method used here. In addition, the presence of an inherited cancer syndrome due to a different genetic cause cannot be ruled out. Any interpretation given here should be clinically correlated with available information about presentation and the patient's relevant family history.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Next generation sequencing, array-based comparative genomic hybridization (aCGH), and multiplex ligation-dependent probe amplification (MLPA) platforms. The entire coding regions, as well as all flanking noncoding regions, of 27 cancer genes known to be involved in the development and progression of cancers are analyzed by next-generation sequencing. Flanking regions for the BRCA1 and BRCA2 genes include ±20 bp and ±10 bp for all other genes. Copy number variations are assessed by aCGH or MLPA to detect deletions and duplications.
Blood is collected by routine phlebotomy.
Causes for Rejection
Frozen specimen; leaking tube; clotted specimen; grossly hemolyzed specimen; incorrect anticoagulant
Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. See sample physician office consent form (Informed Consent for VistaSeq℠) in Related Documents. A Hereditary Cancer Clinical Questionnaire also should be submitted with specimens. Contact CMBP genetics services at 800-345-4363 to coördinate testing.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|481220||VistaSeq Hered. Cancer Panel||481239||Specimen Type||31208-2|
|481220||VistaSeq Hered. Cancer Panel||481226||Preauthorization||N/A|
|481220||VistaSeq Hered. Cancer Panel||481244||Result Summary||51968-6|
|481220||VistaSeq Hered. Cancer Panel||481247||Result and Interpretation||69548-6|
|481220||VistaSeq Hered. Cancer Panel||481248||Recommendations||47042-7|
|481220||VistaSeq Hered. Cancer Panel||481249||Additional Information||77202-0|
|481220||VistaSeq Hered. Cancer Panel||481250||Methodology and Limitations||49549-9|
|481220||VistaSeq Hered. Cancer Panel||481251||References||75608-0|
|481220||VistaSeq Hered. Cancer Panel||481252||Director Review||72486-4|
|481220||VistaSeq Hered. Cancer Panel||481253||51969-4|